

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

185,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



The Role of Vitamin D in the Prevention and Treatment of Prostate Cancer

Sophia L. Maund and Scott D. Cramer
Wake Forest University School of Medicine
University of Colorado, Denver Anschutz Medical Campus
 USA

1. Introduction

Prostate cancer is the most common non-cutaneous cancer in American men and the second most deadly (Jemal et al., 2010). One in six American men will get prostate cancer in his lifetime, and the risk increases with age. Prostate cancer progresses over the course of decades, so there is ample opportunity for prevention earlier in life. Epidemiological and laboratory studies point to vitamin D₃ as a promising chemopreventative agent for prostate cancer. Vitamin D₃ metabolites and analogs have been shown to induce cell cycle arrest, differentiation, and senescence in normal prostate cells and prostate cancer cells. Ongoing studies are interrogating the mechanistic effects behind vitamin D₃ actions in the prostate. Additionally, clinical trials aim to investigate the potential chemopreventative and therapeutic effects of vitamin D₃ metabolites and analogs, both alone and in combination with taxol-based chemotherapeutic agents. Herein we will summarize the epidemiological, laboratory, and clinical studies with vitamin D₃ and the prostate and discuss how the current data supports a role for vitamin D₃ in the prevention and treatment of prostate cancer.

2. Prostate cancer treatment and prevention

If prostate cancer is thought to be localized to the prostate and is classified as low-grade, “watchful waiting” is an option, since some prostate tumors do not become life-threatening. Otherwise, a prostatectomy or external beam radiation is the first line of therapy (or in some cases, brachytherapy). Both prostatectomy and radiation therapy can damage the nerves that rest along the prostate, so side effects include impotence and incontinence that may or may not reverse over time. If the cancer is thought to have spread beyond the prostate, then a more systematic therapeutic approach is needed.

Since androgens are required for growth of both normal prostate cells and most prostate cancer cells, androgen ablation therapy is standard in the forms of surgical or chemical castration. Castration has significant side effects, but it reduces tumor burden and metastases and it can help ease pain from metastatic outgrowths. However, androgen deprivation therapy inherently selects for prostate cancer cells that can grow in the absence of androgens, which often leads to tumor recurrence in 18 to 24 months in the form of castration-resistant prostate cancer (Feldman & Feldman, 2001). The median survival time

for patients with castration-resistant prostate cancer is only 12-18 months. There is no standard successful treatment for castration-resistant prostate cancer, but therapies include docetaxel or paclitaxel-based chemotherapy, which are palliative at best. The impacts on quality of life and the success rates of current treatment options for prostate cancer (especially for castration-resistant prostate cancer) highlight the need for improved therapeutic approaches and the importance of chemoprevention, especially in men who are at higher risks for prostate cancer.

The American Cancer Society states that some cases of prostate cancer may be prevented by maintaining a healthy lifestyle and by hormonal control. Men who take Finasteride, a 5-alpha reductase inhibitor, which is a treatment for benign prostatic hyperplasia (BPH) and male-pattern baldness, have a lower incidence of prostate cancer, but this drug is not widely used for its chemopreventative properties (Hamilton et al., 2010). Dietary sources of chemoprevention are promising, but clinical studies are lacking due to the time and funds required to carry them out (Thompson et al., 2005). One of the most promising dietary chemopreventative agents for prostate cancer is vitamin D₃, which we will discuss in detail below.

3. Prostate cancer risk factors

The major risk factors for prostate cancer include age, race, family history, and geographic location. Prostate cancer develops over the course of decades, so its incidence and detection rates increase with age. Men of African-American descent are almost twice as likely to get prostate cancer as Caucasian men, and the prostate cancer mortality rate is more than twice as high for African-American men (Jemal, et al., 2010). Conversely, Asian men have among the lowest prostate cancer incidence and mortality rates in the world. Interestingly, prostate cancer risk increases in Asian men who relocate to the United States, which emphasizes the contributions of diet and lifestyle to prostate cancer risk (Severson et al., 1989; Luo et al., 2004). Prostate cancer can also have a strong heritable component. The estimated lifetime risk for prostate cancer increases with the number of family members diagnosed, with up to a 45% increase for men with three or more relatives with prostate cancer (Bratt, 2002). The heritable component of prostate cancer is attributed to a number of heritable genetic and epigenetic aberrations, reviewed elsewhere (Nelson et al., 2003).

3.1 Prostate cancer risk factors and vitamin D₃

Of the major risk factors for prostate cancer, age, race, and geographic location are closely tied to vitamin D₃ status. Older men get less sun exposure and have a thinner epidermis (in which UV light synthesizes vitamin D₃) than younger men, which are two reasons why older men have lower serum vitamin D₃ levels (MacLaughlin & Holick, 1985; Lips, 2001). Studies have shown inverse correlations between prostate cancer incidence and geographical regions with less exposure to UV radiation (Hanchette & Schwartz, 1992). Prostate cancer risk and mortality rates are at least twice as high in African-American men than in Caucasian men, and one reason for this may be the high levels of melanin in the skin that blocks UV-induced synthesis of vitamin D₃ (Matsuoka et al., 1991). Japanese men have very low risks for prostate cancer and have among the highest serum vitamin D₃ levels in the world due to the traditional vitamin D₃-rich diet (Nakamura et al., 2000).

These and other epidemiological studies support a role for vitamin D₃ in prostate cancer prevention.

4. Vitamin D₃ metabolism

Vitamin D was discovered in 1920 and characterized as a vitamin that is necessary for skeletal development and calcium homeostasis (Mellanby, 1921). Its chemical structure later revealed that vitamin D is not a vitamin, but a seco-steroid hormone belonging to the steroid hormone family that can be synthesized in the body or obtained from the diet (Brockmann, 1936; Lawson et al., 1971). Vitamin D₃ can be synthesized upon exposure to sunlight or obtained from dietary sources such as oily fish, eggs, and fortified milk. Upon exposure to UV radiation, 7-dehydrocholesterol in the skin is converted to vitamin D₃, also known as cholecalciferol (Figure 1). Vitamin D₃ is the natural form of vitamin D obtained from the diet (DeLuca, 2004). Vitamin D₃ travels to the liver where vitamin D₃ 25-hydroxylase (25-OHase, encoded by the cytochrome P450 enzyme CYP27A1) hydroxylates it to become 25-hydroxyvitamin D₃ (25OHD₃) (Blunt et al., 1968). 25OHD₃ then enters the kidney where 25 hydroxyvitamin D₃ 1 α -hydroxylase (1 α -OHase, encoded by CYP27B1) hydroxylates it at the 1 α position, generating the hormonally active form 1,25 dihydroxyvitamin D₃ (1,25(OH)₂D₃) (Fraser & Kodicek, 1970). 1,25(OH)₂D₃ then travels to target tissues to carry out its effects such as regulating mineral homeostasis. Tissues other than the kidney express endogenous 1 α -OHase such as the bone, liver, placenta, macrophages, skin, breast, colon, and prostate, so 25OHD₃ can be activated directly in these tissues (Schwartz et al., 1998; Zehnder et al., 2001).

Once activated, 1,25(OH)₂D₃ (also known as calcitriol) can bind the vitamin D receptor (VDR) within the cytosol (Figure 2). Upon binding, conformational changes occur that expose the retinoid X receptor (RXR) dimerization domains and the nuclear localization domains, allowing the VDR and the RXR to heterodimerize and enter the nucleus (Yasmin et al., 2005). Nuclear receptor co-activators such as DRIP/Mediator and SRC/p160 associate with the 1,25(OH)₂D₃ -VDR-RXR complex and regulate its transcriptional activity (Rachez & Freedman, 2000; MacDonald et al., 2001). The conformational change also causes the release of co-repressors such as nuclear co-repressors (NCoRs) and the silencing mediator for retinoid and thyroid hormone receptors (SMRT) histone deacetylase complex, allowing histones to be released and the 1,25(OH)₂D₃ -VDR-RXR complex to bind the vitamin D response element (VDRE) in the promoters of target genes (Tagami et al., 1998). RNA polymerase II (RNA Pol II) is recruited to the transcriptional machinery complex and transcribes 1,25(OH)₂D₃ target genes.

Plasma 1,25(OH)₂D₃ levels are tightly regulated by a negative feedback loop because high levels of 1,25(OH)₂D₃ can be toxic. One of the universal 1,25(OH)₂D₃ -VDR-RXR target genes is CYP24A1, which encodes 24-hydroxylase (24-OHase). 24-OHase hydroxylates 1,25(OH)₂D₃ at the 24 position, which targets it for further oxidation to C23 carboxylic acid which is catabolized to calcitroic acid and excreted from the body (Figure 1) (Prosser & Jones, 2004). Normal serum circulation levels of 25OHD₃ are 30-50 ng/mL, while normal serum levels of 1,25(OH)₂D₃ are only ~30 pg/mL (Shepard et al., 1979; Horst & Littledike, 1982). 1,25(OH)₂D₃ circulates bound to the vitamin D binding protein (DBP) from which it disassociates before entering the cell (Arnaud & Constans, 1993). Responses to vitamin D₃ intake differ among individuals and among tissue-types due to variables including CYP24A1 levels, kidney function, and genetic and epigenetic differences in vitamin D₃ metabolic proteins.




Fig. 1. Vitamin D₃ metabolism.




Fig. 2. Intracellular trafficking of 1,25(OH)₂D₃.

5. Vitamin D₃ epidemiology

There is an established association between increased prostate cancer risk and mortality and low serum 25OHD₃ levels (Ahonen et al., 2000; Tretli et al., 2009), as well as an association between prostate cancer risk and genetic polymorphisms of the VDR (Ingles et al., 1997). However, other studies report no association or even a positive association between serum 25OHD₃ and prostate cancer risk (Nomura et al., 1998; Park et al., 2010). The inconsistencies among reports warrant improved investigation and evaluation methods (reviewed in (Trottier et al., 2010)). One reason for the inconsistencies could be the apparent impact on prostate cancer risk of vitamin D₃ exposure over the course of a lifetime as opposed to the impact of serum levels of 25OHD₃ over a defined time period (John et al., 2004; John et al., 2007); studies have shown that childhood sunburn frequency and UV exposure correlates with lower prostate cancer risks (Luscombe et al., 2001; Bodiwala et al., 2003). Another reason could be that, since prostate cancer develops over the course of decades, some patients' cancer cells may have lost the ability to activate 25OHD₃ to 1,25(OH)₂D₃ (Guileyardo et al., 1980; J. Y. Hsu et al., 2001; Chen et al., 2003). Studies with follow-up periods greater than 10 years are better for evaluating the implications of vitamin D₃ status in prostate cancer development (Ahonen, et al., 2000; Li et al., 2007). Additionally, intermittent high doses (>100,000 IU) of vitamin D₃ may be metabolized differently from lower daily doses (Rosen, 2011). There is no standardization for vitamin D₃, 25OHD₃ or 1,25(OH)₂D₃ administration, which has hampered clinical studies. Overall, the epidemiological studies encourage more laboratory and clinical investigations into a therapeutic role for vitamin D₃ and its metabolites in the prevention and treatment of prostate cancer.

6. *In vitro* and *in vivo* studies

As mentioned above, prostate cells express endogenous 1 α -OHase and can synthesize 1,25(OH)₂D₃ from 25(OH)D₃, which suggests an important role for 1,25(OH)₂D₃ in prostate biology (Schwartz, et al., 1998). We and others have shown that 25OHD₃ inhibits prostate epithelial cell growth and induces p21 and p27 (common downstream targets of 1,25(OH)₂D₃) to the same extents as does 1,25(OH)₂D₃ (Barreto et al., 2000). This supports the application of 25OHD₃ as a therapeutic that targets prostate tissue. Interestingly, 1 α -OHase activity is lost and 24-OHase expression is elevated in prostate cancer cells compared to normal prostate cells, which supports a correlation between decreased 1,25(OH)₂D₃ levels and prostate cancer (Miller et al., 1995; Whitlatch et al., 2002).

One of the ways that 1,25(OH)₂D₃ is thought to maintain prostate homeostasis is by keeping cell growth in check. 1,25(OH)₂D₃-induced apoptosis is rarely observed. LNCaP cells treated with 1,25(OH)₂D₃ undergo cell cycle arrest at G1 as a result of increased p21 and p27 levels and decreased CDK2 activity followed by dephosphorylation of retinoblastoma (pRB) and subsequent suppression of E2F transcriptional activity (Figure 3) (Zhuang & Burnstein, 1998; Yang & Burnstein, 2003). Two of the most common downstream targets of 1,25(OH)₂D₃ are CDKN1A (which encodes p21) and CDKN1B (which encodes p27). 25OHD₃, 1,25(OH)₂D₃, and its analogs have been shown to elevate p21 and p27 expression in several tissue types in conjunction with cell growth inhibition (Kawa et al., 1997; Barreto, et al., 2000; Colston & Hansen, 2002). CDKN1A contains a VDRE, so its transcription can be directly regulated by 1,25(OH)₂D₃. 1,25(OH)₂D₃ can also elevate p21 indirectly through direct transcriptional

induction of insulin-like growth factor binding protein-3 (IGFBP-3), an upstream mediator of p21 transcription (Boyle et al., 2001; Peng et al., 2004; Peng et al., 2008). CDKN1B does not contain a VDRE, so p27 is regulated indirectly by 1,25(OH)₂D₃. CDK2 activates SKP2-mediated degradation of p27, so 1,25(OH)₂D₃-mediated induction of p27 is likely due to inhibition of CDK2 and p27 protein stabilization (Yang & Burnstein, 2003).




Fig. 3. 1,25(OH)₂D₃ signaling leading to G1 cell cycle arrest in prostate cancer cells.

More recently, 1,25(OH)₂D₃ has been shown to inhibit E2F and/or induce G1 arrest independently from pRB (Figure 3). In the C4-2 prostate cancer cell line, 1,25(OH)₂D₃ inhibited cMYC which subsequently suppressed E2F activity and cell cycle progression regardless of pRB status (Washington et al., 2011). We have reported that 1,25(OH)₂D₃ induces cell cycle arrest independently from pRB in prostate progenitor/stem cells (Maund et al., 2011). Flores and Burnstein recently reported that the cell cycle inhibitory protein GADD45γ mediates 1,25(OH)₂D₃-induced accumulation of LNCaP cells in G1 (Flores & Burnstein, 2010). Cell cycle arrest in G1 is a common downstream effect of 1,25(OH)₂D₃ treatment, and additional mechanisms of cell cycle regulation by 1,25(OH)₂D₃ are still being uncovered. 1,25(OH)₂D₃ can induce differentiation of several cell types including prostate stem cells, prostate epithelial cells and prostate cancer cells (Miller et al., 1992; Tokar & Webber, 2005; Maund, et al., 2011). Differentiated prostate cells do not normally divide, so 1,25(OH)₂D₃ may slow or halt any aberrant cell division. 1,25(OH)₂D₃-induced differentiation of the LNCaP prostate cancer cell line is evidenced by increased levels of prostate-specific antigen (PSA), kallikrein 2, E-cadherin, and androgen receptor (AR) (Esquenet et al., 1996; Campbell et al., 1997; Zhao et al., 1997; Darson et al., 1999; Zhao et al., 1999; Tokar & Webber, 2005). AR signaling plays critical roles in prostate development, function, and pathogenesis. We reported that prostate progenitor/stem cells are AR-negative but, upon treatment with 1,25(OH)₂D₃, they become AR-positive (Barclay et al., 2008; Maund, et al., 2011). AR is not a direct transcriptional target of 1,25(OH)₂D₃ because it does not contain a VDRE, but we did

observe increased AR mRNA in response to $1,25(\text{OH})_2\text{D}_3$; its mechanism of upregulation is unclear (Zhao, et al., 1999). Since AR signaling can contribute to prostate tumor growth, the induction of AR by $1,25(\text{OH})_2\text{D}_3$ may not be considered an anti-tumor effect. However, the induction of AR by $1,25(\text{OH})_2\text{D}_3$ signifies a transition from a less-differentiated prostate cell toward a more-differentiated prostate cell that is either less likely to become cancerous or, if already transformed, more responsive to therapeutic intervention such as castration. These hypotheses have yet to be tested *in vivo*. In LNCaP cells, growth inhibition by $1,25(\text{OH})_2\text{D}_3$ has been shown to be dependent on AR (Miller, et al., 1992; Zhao, et al., 1997; Zhao et al., 2000). AR-mediated induction of IGFBP-3 has been implicated in this process (Peng, et al., 2008). The exact mechanism(s) of $1,25(\text{OH})_2\text{D}_3$ -induced differentiation is unknown, though differentiation is often preceded by an enrichment of cells in the G1 phase of the cell cycle (Studzinski & Harrison, 1999). Upregulation of p21 and p27 are implicated in differentiation of LNCaP and PC3 cells, and p27 is involved in senescence in a mouse model of prostate cancer (Campbell, et al., 1997; Majumder et al., 2008). This suggests that accumulation of prostate cells in G1 may precede $1,25(\text{OH})_2\text{D}_3$ -induced differentiation and/or senescence, but the mechanisms remain unknown.

Our group recently reported that $1,25(\text{OH})_2\text{D}_3$ can induce senescence of prostate cancer cells *in vitro* (Axanova et al., 2010). Senescence is defined as a terminally-arrested state in which cells are metabolically active but cannot resume cell cycle progression (Muller, 2009), so induction of senescence is an additional form of $1,25(\text{OH})_2\text{D}_3$ -mediated growth suppression. Senescence has been observed in cases of PIN that do not progress to prostate cancer (Majumder, et al., 2008), so it is possible that additional senescence induced by $1,25(\text{OH})_2\text{D}_3$ may impede prostate cancer progression. This has yet to be tested *in vivo*.

Another way that $1,25(\text{OH})_2\text{D}_3$ may impede prostate cancer progression and metastasis is through inhibition of cellular invasion and migration. *In vitro* studies have shown that $1,25(\text{OH})_2\text{D}_3$ decreases expression of alpha-6 and beta-4 integrins to inhibit the invasive capacities of prostate cancer cell lines (Sung & Feldman, 2000). $1,25(\text{OH})_2\text{D}_3$ is known to induce E-cadherin in prostate cancer cells (Campbell, et al., 1997), and E-cadherin was recently reported to mediate $1,25(\text{OH})_2\text{D}_3$ -induced cellular adhesion that mitigates the metastatic capabilities of prostate cancer cells (J. W. Hsu et al., 2011). $1,25(\text{OH})_2\text{D}_3$ has also been shown to regulate a range of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs), also thought to mediate the effects of $1,25(\text{OH})_2\text{D}_3$ on invasion of prostate cancer cells (Bao et al., 2006).

In vivo studies with $1,25(\text{OH})_2\text{D}_3$ have been carried out primarily in xenograft models of prostate cancer as well as in the Dunning rat model of prostate cancer and, more recently, the Nkx3.1^{+/}-PTEN^{+/}- mouse model (Getzenberg et al., 1997; Lokeshwar et al., 1999; Banach-Petrosky et al., 2006; Trump et al., 2006). In the rat Dunning model, $1,25(\text{OH})_2\text{D}_3$ and $1,25(\text{OH})_2\text{D}_3$ analogs decreased tumor volumes and lung metastases, but the animals developed hypercalcemia. Use of $1,25(\text{OH})_2\text{D}_3$ analogs alone, however, were sufficient to reduce PC3 and LNCaP xenograft volumes without inducing hypercalcemia (Schwartz et al., 1995; Blutt et al., 2000). Nkx3.1^{+/}-PTEN^{+/}- mutant mice develop high-grade PIN with the capacity for progression to advanced metastatic and androgen-independent prostate cancer (Kim et al., 2002; Abate-Shen et al., 2003). Sustained intravenous delivery of 46 ng/kg/day of $1,25(\text{OH})_2\text{D}_3$ or vehicle control were administered to Nkx3.1^{+/}-PTEN^{+/}- pre-cancerous and cancerous cohorts of mice for 4 months (Banach-Petrosky, et al., 2006). Interestingly, $1,25(\text{OH})_2\text{D}_3$ suppressed PIN formation in the pre-cancerous cohort, but it did not affect prostate cancer progression in the cancerous cohort. Furthermore, increased levels of the

VDR were observed in the pre-cancerous cohort after $1,25(\text{OH})_2\text{D}_3$ administration, while there was only a modest increase in VDR in the cancerous cohort, which could account for the ineffectiveness of $1,25(\text{OH})_2\text{D}_3$ on tumor progression in the cancerous cohort. These results suggest that prostate cancer cells may have aberrations in the vitamin D_3 response pathway. Therefore, vitamin D_3 may be more effective as a chemopreventative agent than as a chemotherapeutic.

6.1 Prostate stem cells and vitamin D_3

Accumulating evidence supports the presence of adult prostate-specific stem cells, which undergo self-renewal into an identical prostate stem cell and multi-lineage differentiation into the multiple epithelial cell types of the prostate (Burger et al., 2005; Barclay, et al., 2008; Goldstein et al., 2010). They serve to maintain prostate tissue homeostasis and to stimulate tissue regeneration after injury. There are many similarities between the signalling pathways found to regulate stem cell processes and those that regulate cancer progression, which has led to the cancer stem cell hypothesis (Reya et al., 2001; Maund & Cramer, 2009; Mimeault & Batra, 2010). The prostate cancer stem cell hypothesis proposes that a transformed prostate stem cell can give rise to a heterogeneous prostate tumor, and that the tumor cannot be ablated unless the cancer stem cells are eliminated.

The aim of chemoprevention is to impede tumor development at the earliest point in its progression. According to the cancer stem cell hypothesis, the target cell population for prostate cancer prevention would be the prostate stem/progenitor cells (Maund & Cramer, 2010). Stem cells intrinsically have an extended replicative capacity. Agents that limit this capacity and promote differentiation are promising chemopreventative agents. We have recently reported that $1,25(\text{OH})_2\text{D}_3$ is growth-inhibitory in adult prostate stem/progenitor cells (Maund, et al., 2011). $1,25(\text{OH})_2\text{D}_3$ can induce G1 and G2 cell cycle arrest, stimulate differentiation toward a luminal epithelial cell type, and trigger senescence in this cell population, supporting a relevant role for vitamin D_3 in prostate chemoprevention (particularly in light of the cancer stem cell hypothesis). We found that the cytokine interleukin-1 alpha is highly upregulated by $1,25(\text{OH})_2\text{D}_3$ and is a novel mediator of $1,25(\text{OH})_2\text{D}_3$ -induced growth inhibition of prostate stem/progenitor cells. In addition, microarray data revealed that $1,25(\text{OH})_2\text{D}_3$ can impact gene expression and signalling pathways involved in stem cell self-renewal and multilineage differentiation including Hedgehog, Wnt, and $\text{TGF}\beta$ signaling (Maund, et al., 2011). $1,25(\text{OH})_2\text{D}_3$ regulates components of these pathways in other cell types as well (Sarkar et al., 2010; Tang et al., 2011). This work is just beginning to reveal the cellular and genomic impacts of $1,25(\text{OH})_2\text{D}_3$ in the stem cell population. Furthermore, $1,25(\text{OH})_2\text{D}_3$ has been shown to exert anti-proliferative and pro-differentiating effects on hematopoietic and skin progenitor cells (Liu et al., 1996; Lehmann et al., 2010). The identification of tissue-specific stem cells and their potential contributions to cancer initiation and progression is changing the way we approach cancer prevention and treatment. A major aim is to identify compounds that effectively target the stem cell population, and $1,25(\text{OH})_2\text{D}_3$ is a promising candidate for further investigation.

7. Clinical studies

Most clinical trials involving $1,25(\text{OH})_2\text{D}_3$ and $1,25(\text{OH})_2\text{D}_3$ analogs are carried out in combination with chemotherapeutic agents, particularly the taxanes, and are tested in patients with castration-resistant prostate cancer. $1,25(\text{OH})_2\text{D}_3$ analogs such as EB1089 and

22-oxacalcitriol (OCT) are VDR ligands designed to recapitulate the anti-proliferative effects of $1,25(\text{OH})_2\text{D}_3$ while minimizing the effects on calcium homeostasis that often lead to hypercalcemia (Steddon et al., 2001). To date, no $1,25(\text{OH})_2\text{D}_3$ analog has fared significantly better than $1,25(\text{OH})_2\text{D}_3$ alone. There are still many studies missing that are necessary for designing accurate clinical trials with $1,25(\text{OH})_2\text{D}_3$ and $1,25(\text{OH})_2\text{D}_3$ analogs including determination of the maximum-tolerated and optimal doses, definitions of phase II single-agent and combination doses, and randomized phase II trials that compare $1,25(\text{OH})_2\text{D}_3$ alone versus $1,25(\text{OH})_2\text{D}_3$ in combination with a single chemotherapeutic agent. These issues must be resolved in order to generate accurate phase II and phase III clinical trial data (Trump et al., 2010).

A high-dose formulation of $1,25(\text{OH})_2\text{D}_3$ called DN-101 was tested for safety and efficacy in the ASCENT I (Androgen-independent prostate cancer Study of Calcitriol Enhancement of Taxotere) phase II trial in combination with docetaxel (Brawer, 2007). DN-101 administration was associated with improved survival but it did not impact PSA response (Beer et al., 2007). A large phase III trial (ASCENT II) was terminated in 2007 due to greater death rates in the experimental arm (docetaxel, prednisone, and DN-101) than the control arm (docetaxel, prednisone, and placebo). However, ASCENT II was not accurately designed to test the efficacy of DN-101 versus the placebo (Trump, et al., 2010). The docetaxel administration schedule and the DN-101 dosages were not consistent with those previously established. Since the optimal dose and maximum-tolerated dose for oral $1,25(\text{OH})_2\text{D}_3$ remain undefined, the DN-101 doses used in the ASCENT trials were based on convenience: a weekly oral dose of $0.5 \mu\text{g}/\text{kg}$. In pre-clinical trials, however, intravenous administration of $>1 \mu\text{g}/\text{kg}$ $1,25(\text{OH})_2\text{D}_3$ was required for anti-tumor effects (Trump, et al., 2010). Although the results from the ASCENT II trial were ambiguous, they highlighted several questions that need to be resolved before designing new $1,25(\text{OH})_2\text{D}_3$ clinical trials.

Vitamin D_3 oral supplementation doses are still being defined; they vary depending on the desired endpoint and on individual vitamin D_3 metabolic capacity (Bischoff-Ferrari, 2009). Individuals with serum 25OHD_3 levels less than $30 \text{ ng}/\text{mL}$ are considered to be vitamin D_3 deficient. A recent retrospective analysis measured the impact of $8,000 \text{ IU}/\text{day}$ vitamin D_3 supplementation on 25OHD_3 levels in 2198 cancer patients (Vashi et al., 2010). They found that patients with baseline 25OHD_3 levels between 20 and $32 \text{ ng}/\text{mL}$ responded to supplementation better than those with baseline levels $<20 \text{ ng}/\text{mL}$. Additionally, patients with prostate cancer were the most responsive to vitamin D_3 supplementation, in terms of the number of individuals whose 25OHD_3 levels were $>32 \text{ ng}/\text{mL}$ after 8 weeks of supplementation. This finding supports further clinical investigations of vitamin D_3 in prostate cancer prevention and treatment. This study reported that $8,000 \text{ IU}/\text{day}$ for 8 weeks was a safe and effective regimen for prostate and lung cancer patients, and they suggested that supplementation levels should be higher in colorectal and pancreatic cancer patients (Vashi, et al., 2010). Further studies are required to define maximum-tolerated and optimal doses for patients with different types of cancers.

The range of serum 25OHD_3 associated with cancer prevention is $60\text{--}80 \text{ ng}/\text{mL}$ (CF Garland et al., 2009). A recent community-based study of voluntary vitamin D_3 supplementation sought to define the doses necessary to reach serum 25OHD_3 levels in this range (C. F. Garland et al., 2011). They reported that total vitamin D_3 intake from $9,400$ to $17,400 \text{ IU}/\text{day}$ would be necessary to achieve serum 25OHD_3 levels of $30\text{--}50 \text{ ng}/\text{mL}$ in this population. Additionally, they reported no toxicity from up to $40,000 \text{ IU}/\text{day}$. They proposed that most individuals should supplement their vitamin D_3 intake by $4,000\text{--}8,000 \text{ IU}/\text{day}$ in order to

reach serum 25OHD₃ levels associated with cancer prevention. This study will help shape additional clinical trials for vitamin D₃-based chemoprevention, and in the meantime it will help inform the public about the importance of sufficient vitamin D₃ supplementation. However, there is much controversy over the recommended vitamin D₃ supplementation doses. In 2010 the Institute of Medicine recommended a daily dose of 600 IU vitamin D₃, with a tolerable upper limit of 4,000 IU/day. However, the long-term benefits of vitamin D₃ doses in this range are unknown, and others (such as C.F. Garland et al., 2011 and Vashi et al., 2010) argue that 600 IU is insufficient for significant clinical benefits and that the tolerable upper limit exceeds 4,000 IU/day. It is becoming clear that the optimal daily vitamin D₃ dose is dependent on 1) the individual's baseline serum 25OHD₃ level, 2) the individual's vitamin D₃ metabolic capacity, and 3) the individual's health status and lifestyle (diabetic, prostate cancer vs. colorectal cancer patient, etc.). For these reasons and for the lack of definitive clinical studies there is controversy surrounding universal recommended vitamin D₃ doses. Future work should focus on resolving this continuing controversy.

8. Conclusion

Further understanding of the mechanisms of action behind 1,25(OH)₂D₃ signaling in the prostate and a deeper understanding of prostate stem cell biology will help potentiate the chemopreventative effects of vitamin D₃ and promote its concomitant use in primary and adjuvant prostate cancer therapies. Prostate cancer is a slow-growing disease that develops over the course of decades and typically affects men late in life. Treatment decisions are based on tumor severity and rate of PSA change, and some prostate tumors do not even progress to stages necessary for therapeutic intervention. The aim of prostate cancer chemoprevention is to delay tumor onset and progression. Chemopreventative strategies that delay prostate tumor onset or progression by even five years will drastically decrease the incidence of clinically-relevant prostate cancer and will reduce the need for prostate cancer treatment. Current findings that 1,25(OH)₂D₃, the metabolically active form of naturally-derived and FDA-approved vitamin D₃, is effective in regulating prostate progenitor/stem cell growth and differentiation supports the use of vitamin D₃ as a safe and effective chemopreventative agent for prostate cancer. Thorough studies assessing the efficacy of vitamin D₃ or its analogs in the clinical therapeutic setting are still needed.

9. References

- Abate-Shen, C., Banach-Petrosky, W.A., Sun, X., Economides, K.D., Desai, N., Gregg, J.P., Borowsky, A.D., Cardiff, R.D. & Shen, M.M. (2003). Nkx3.1; Pten Mutant Mice Develop Invasive Prostate Adenocarcinoma and Lymph Node Metastases. *Cancer Res*, Vol.63, No.14, (Jul 15), pp. 3886-3890, 0008-5472
- Ahonen, M.H., Tenkanen, L., Teppo, L., Hakama, M. & Tuohimaa, P. (2000). Prostate Cancer Risk and Prediagnostic Serum 25-Hydroxyvitamin D Levels (Finland). *Cancer Causes Control*, Vol.11, No.9, (Oct), pp. 847-852, 0957-5243
- Arnaud, J. & Constans, J. (1993). Affinity Differences for Vitamin D Metabolites Associated with the Genetic Isoforms of the Human Serum Carrier Protein (Dbp). *Hum Genet*, Vol.92, No.2, (Sep), pp. 183-188, 0340-6717

- Axanova, L.S., Chen, Y.Q., McCoy, T., Sui, G. & Cramer, S.D. (2010). 1,25-Dihydroxyvitamin D(3) and Pi3k/Akt Inhibitors Synergistically Inhibit Growth and Induce Senescence in Prostate Cancer Cells. *Prostate*, Vol.70, No.15, (Nov 1), pp. 1658-1671, 1097-0045
- Banach-Petrosky, W., Ouyang, X., Gao, H., Nader, K., Ji, Y., Suh, N., DiPaola, R.S. & Abate-Shen, C. (2006). Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1;Pten Mutant Mice. *Clin Cancer Res*, Vol.12, No.19, (Oct 1), pp. 5895-5901, 1078-0432
- Bao, B.Y., Yeh, S.D. & Lee, Y.F. (2006). 1 α ,25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Invasion Via Modulation of Selective Proteases. *Carcinogenesis*, Vol.27, No.1, (Jan), pp. 32-42, 0143-3334
- Barclay, W.W., Axanova, L.S., Chen, W., Romero, L., Maund, S.L., Soker, S., Lees, C.J. & Cramer, S.D. (2008). Characterization of Adult Prostatic Progenitor/Stem Cells Exhibiting Self-Renewal and Multilineage Differentiation. *Stem Cells*, Vol.26, No.3, (Mar), pp. 600-610, 1549-4918
- Barreto, A.M., Schwartz, G.G., Woodruff, R. & Cramer, S.D. (2000). 25-Hydroxyvitamin D3, the Prohormone of 1,25-Dihydroxyvitamin D3, Inhibits the Proliferation of Primary Prostatic Epithelial Cells. *Cancer Epidemiol Biomarkers Prev*, Vol.9, No.3, (Mar), pp. 265-270, 1055-9965
- Beer, T.M., Ryan, C.W., Venner, P.M., Petrylak, D.P., Chatta, G.S., Ruether, J.D., Redfern, C.H., Fehrenbacher, L., Saleh, M.N., Waterhouse, D.M., Carducci, M.A., Vicario, D., Dreicer, R., Higano, C.S., Ahmann, F.R., Chi, K.N., Henner, W.D., Arroyo, A. & Clow, F.W. (2007). Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared with Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report from the Ascent Investigators. *J Clin Oncol*, Vol.25, No.6, (Feb 20), pp. 669-674, 1527-7755
- Bischoff-Ferrari, H. (2009). Vitamin D: What Is an Adequate Vitamin D Level and How Much Supplementation Is Necessary? *Best Pract Res Clin Rheumatol*, Vol.23, No.6, (Dec), pp. 789-795, 1532-1770
- Blunt, J.W., DeLuca, H.F. & Schnoes, H.K. (1968). 25-Hydroxycholecalciferol. A Biologically Active Metabolite of Vitamin D3. *Biochemistry*, Vol.7, No.10, (Oct), pp. 3317-3322, 0006-2960
- Blutt, S.E., Polek, T.C., Stewart, L.V., Kattan, M.W. & Weigel, N.L. (2000). A Calcitriol Analogue, Eb1089, Inhibits the Growth of Lncap Tumors in Nude Mice. *Cancer Res*, Vol.60, No.4, (Feb 15), pp. 779-782, 0008-5472
- Bodiwala, D., Luscombe, C.J., Liu, S., Saxby, M., French, M., Jones, P.W., Fryer, A.A. & Strange, R.C. (2003). Prostate Cancer Risk and Exposure to Ultraviolet Radiation: Further Support for the Protective Effect of Sunlight. *Cancer Lett*, Vol.192, No.2, (Mar 31), pp. 145-149, 0304-3835
- Boyle, B.J., Zhao, X.Y., Cohen, P. & Feldman, D. (2001). Insulin-Like Growth Factor Binding Protein-3 Mediates 1 α ,25-Dihydroxyvitamin D(3) Growth Inhibition in the Lncap Prostate Cancer Cell Line through P21/Waf1. *J Urol*, Vol.165, No.4, (Apr), pp. 1319-1324, 0022-5347

- Bratt, O. (2002). Hereditary Prostate Cancer: Clinical Aspects. *J Urol*, Vol.168, No.3, (Sep), pp. 906-913, 0022-5347
- Brawer, M.K. (2007). Recent Progress in the Treatment of Advanced Prostate Cancer with Intermittent Dose-Intense Calcitriol (Dn-101). *Rev Urol*, Vol.9, No.1, (Winter), pp. 1-8, 1523-6161
- Brockmann, H. (1936). Die Isolierung Des Antirachitischen Vitamins Aus Thunfischleberol. *Hoppe Seylers Z Physiol Chem*, Vol.241, No., pp. 104-115,
- Burger, P.E., Xiong, X., Coetzee, S., Salm, S.N., Moscatelli, D., Goto, K. & Wilson, E.L. (2005). Sca-1 Expression Identifies Stem Cells in the Proximal Region of Prostatic Ducts with High Capacity to Reconstitute Prostatic Tissue. *Proc Natl Acad Sci U S A*, Vol.102, No.20, (May 17), pp. 7180-7185, 0027-8424
- Campbell, M.J., Elstner, E., Holden, S., Uskokovic, M. & Koeffler, H.P. (1997). Inhibition of Proliferation of Prostate Cancer Cells by a 19-nor-Hexafluoride Vitamin D3 Analogue Involves the Induction of P21waf1, P27kip1 and E-Cadherin. *J Mol Endocrinol*, Vol.19, No.1, (Aug), pp. 15-27, 0952-5041
- Chen, T.C., Wang, L., Whitlatch, L.W., Flanagan, J.N. & Holick, M.F. (2003). Prostatic 25-Hydroxyvitamin D-1alpha-Hydroxylase and Its Implication in Prostate Cancer. *J Cell Biochem*, Vol.88, No.2, (Feb 1), pp. 315-322, 0730-2312
- Colston, K.W. & Hansen, C.M. (2002). Mechanisms Implicated in the Growth Regulatory Effects of Vitamin D in Breast Cancer. *Endocr Relat Cancer*, Vol.9, No.1, (Mar), pp. 45-59, 1351-0088
- Darson, M.F., Pacelli, A., Roche, P., Rittenhouse, H.G., Wolfert, R.L., Saeid, M.S., Young, C.Y., Klee, G.G., Tindall, D.J. & Bostwick, D.G. (1999). Human Glandular Kallikrein 2 Expression in Prostate Adenocarcinoma and Lymph Node Metastases. *Urology*, Vol.53, No.5, (May), pp. 939-944, 0090-4295
- DeLuca, H.F. (2004). Overview of General Physiologic Features and Functions of Vitamin D. *Am J Clin Nutr*, Vol.80, No.6 Suppl, (Dec), pp. 1689S-1696S, 0002-9165
- Esquenet, M., Swinnen, J.V., Heyns, W. & Verhoeven, G. (1996). Control of Lncap Proliferation and Differentiation: Actions and Interactions of Androgens, 1alpha,25-Dihydroxycholecalciferol, All-Trans Retinoic Acid, 9-Cis Retinoic Acid, and Phenylacetate. *Prostate*, Vol.28, No.3, (Mar), pp. 182-194, 0270-4137
- Feldman, B.J. & Feldman, D. (2001). The Development of Androgen-Independent Prostate Cancer. *Nat Rev Cancer*, Vol.1, No.1, (Oct), pp. 34-45, 1474-175X
- Flores, O. & Burnstein, K.L. (2010). Gadd45gamma: A New Vitamin D-Regulated Gene That Is Antiproliferative in Prostate Cancer Cells. *Endocrinology*, Vol.151, No.10, (Oct), pp. 4654-4664, 1945-7170
- Fraser, D.R. & Kodicek, E. (1970). Unique Biosynthesis by Kidney of a Biological Active Vitamin D Metabolite. *Nature*, Vol.228, No.5273, (Nov 21), pp. 764-766, 0028-0836
- Garland, C., Gorham, E., Mohr, S. & Garland, F. (2009). Vitamin D for Cancer Prevention: Global Perspective. *Ann Epidemiol*, Vol.19, No.7, (Jul), pp. 468-483, 1873-2585
- Garland, C.F., French, C.B., Baggerly, L.L. & Heaney, R.P. (2011). Vitamin D Supplement Doses and Serum 25-Hydroxyvitamin D in the Range Associated with Cancer Prevention. *Anticancer Res*, Vol.31, No.2, (Feb), pp. 607-611, 1791-7530

- Getzenberg, R.H., Light, B.W., Lapco, P.E., Konety, B.R., Nangia, A.K., Acierno, J.S., Dhir, R., Shurin, Z., Day, R.S., Trump, D.L. & Johnson, C.S. (1997). Vitamin D Inhibition of Prostate Adenocarcinoma Growth and Metastasis in the Dunning Rat Prostate Model System. *Urology*, Vol.50, No.6, (Dec), pp. 999-1006, 0090-4295
- Goldstein, A.S., Stoyanova, T. & Witte, O.N. (2010). Primitive Origins of Prostate Cancer: In Vivo Evidence for Prostate-Regenerating Cells and Prostate Cancer-Initiating Cells. *Mol Oncol*, Vol.4, No.5, (Oct), pp. 385-396, 1878-0261
- Guileyardo, J.M., Johnson, W.D., Welsh, R.A., Akazaki, K. & Correa, P. (1980). Prevalence of Latent Prostate Carcinoma in Two U.S. Populations. *J Natl Cancer Inst*, Vol.65, No.2, (Aug), pp. 311-316, 0027-8874
- Hamilton, R.J., Kahwati, L.C. & Kinsinger, L.S. (2010). Knowledge and Use of Finasteride for the Prevention of Prostate Cancer. *Cancer Epidemiol Biomarkers Prev*, Vol.19, No.9, (Sep), pp. 2164-2171, 1538-7755
- Hanchette, C.L. & Schwartz, G.G. (1992). Geographic Patterns of Prostate Cancer Mortality. Evidence for a Protective Effect of Ultraviolet Radiation. *Cancer*, Vol.70, No.12, (Dec 15), pp. 2861-2869, 0008-543X
- Horst, R.L. & Littledike, E.T. (1982). Comparison of Plasma Concentrations of Vitamin D and Its Metabolites in Young and Aged Domestic Animals. *Comp Biochem Physiol B*, Vol.73, No.3, pp. 485-489, 0305-0491
- Hsu, J.W., Yasmin-Karim, S., King, M.R., Wojciechowski, J.C., Mickelsen, D., Blair, M.L., Ting, H.J., Ma, W.L. & Lee, Y.F. (2011). Suppression of Prostate Cancer Cell Rolling and Adhesion to Endothelium by 1 α ,25-Dihydroxyvitamin D₃. *Am J Pathol*, Vol.178, No.2, (Feb), pp. 872-880, 1525-2191
- Hsu, J.Y., Feldman, D., McNeal, J.E. & Peehl, D.M. (2001). Reduced 1 α -Hydroxylase Activity in Human Prostate Cancer Cells Correlates with Decreased Susceptibility to 25-Hydroxyvitamin D₃-Induced Growth Inhibition. *Cancer Res*, Vol.61, No.7, (Apr 1), pp. 2852-2856, 0008-5472
- Ingles, S.A., Ross, R.K., Yu, M.C., Irvine, R.A., La Pera, G., Haile, R.W. & Coetzee, G.A. (1997). Association of Prostate Cancer Risk with Genetic Polymorphisms in Vitamin D Receptor and Androgen Receptor. *J Natl Cancer Inst*, Vol.89, No.2, (Jan 15), pp. 166-170, 0027-8874
- Jemal, A., Siegel, R., Xu, J. & Ward, E. (2010). Cancer Statistics, 2010. *CA Cancer J Clin*, Vol.60, No.5, (Sep-Oct), pp. 277-300, 1542-4863
- John, E.M., Dreon, D.M., Koo, J. & Schwartz, G.G. (2004). Residential Sunlight Exposure Is Associated with a Decreased Risk of Prostate Cancer. *J Steroid Biochem Mol Biol*, Vol.89-90, No.1-5, (May), pp. 549-552, 0960-0760
- John, E.M., Koo, J. & Schwartz, G.G. (2007). Sun Exposure and Prostate Cancer Risk: Evidence for a Protective Effect of Early-Life Exposure. *Cancer Epidemiol Biomarkers Prev*, Vol.16, No.6, (Jun), pp. 1283-1286, 1055-9965
- Kawa, S., Nikaido, T., Aoki, Y., Zhai, Y., Kumagai, T., Furihata, K., Fujii, S. & Kiyosawa, K. (1997). Vitamin D Analogues up-Regulate P21 and P27 During Growth Inhibition of Pancreatic Cancer Cell Lines. *Br J Cancer*, Vol.76, No.7, pp. 884-889, 0007-0920
- Kim, M.J., Cardiff, R.D., Desai, N., Banach-Petrosky, W.A., Parsons, R., Shen, M.M. & Abate-Shen, C. (2002). Cooperativity of Nkx3.1 and Pten Loss of Function in a Mouse

- Model of Prostate Carcinogenesis. *Proc Natl Acad Sci U S A*, Vol.99, No.5, (Mar 5), pp. 2884-2889, 0027-8424
- Lawson, D.E., Fraser, D.R., Kodicek, E., Morris, H.R. & Williams, D.H. (1971). Identification of 1,25-Dihydroxycholecalciferol, a New Kidney Hormone Controlling Calcium Metabolism. *Nature*, Vol.230, No.5291, (Mar 26), pp. 228-230, 0028-0836
- Lehmann, B., Schättiger, K. & Meurer, M. (2010). Conversion of Vitamin D(3) to Hormonally Active 1alpha,25-Dihydroxyvitamin D(3) in Cultured Keratinocytes: Relevance to Cell Growth and Differentiation. *J Steroid Biochem Mol Biol*, Vol., No., (Feb), 1879-1220
- Li, H., Stampfer, M.J., Hollis, J.B., Mucci, L.A., Gaziano, J.M., Hunter, D., Giovannucci, E.L. & Ma, J. (2007). A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer. *PLoS Med*, Vol.4, No.3, (Mar), pp. e103, 1549-1676
- Lips, P. (2001). Vitamin D Deficiency and Secondary Hyperparathyroidism in the Elderly: Consequences for Bone Loss and Fractures and Therapeutic Implications. *Endocr Rev*, Vol.22, No.4, (Aug), pp. 477-501, 0163-769X
- Liu, M., Lee, M.H., Cohen, M., Bommakanti, M. & Freedman, L.P. (1996). Transcriptional Activation of the Cdk Inhibitor P21 by Vitamin D3 Leads to the Induced Differentiation of the Myelomonocytic Cell Line U937. *Genes Dev*, Vol.10, No.2, (Jan 15), pp. 142-153, 0890-9369
- Lokeshwar, B.L., Schwartz, G.G., Selzer, M.G., Burnstein, K.L., Zhuang, S.H., Block, N.L. & Binderup, L. (1999). Inhibition of Prostate Cancer Metastasis in Vivo: A Comparison of 1,23-Dihydroxyvitamin D (Calcitriol) and Eb1089. *Cancer Epidemiol Biomarkers Prev*, Vol.8, No.3, (Mar), pp. 241-248, 1055-9965
- Luo, W., Birkett, N.J., Ugnat, A.M. & Mao, Y. (2004). Cancer Incidence Patterns among Chinese Immigrant Populations in Alberta. *J Immigr Health*, Vol.6, No.1, (Jan), pp. 41-48, 1096-4045
- Luscombe, C.J., Fryer, A.A., French, M.E., Liu, S., Saxby, M.F., Jones, P.W. & Strange, R.C. (2001). Exposure to Ultraviolet Radiation: Association with Susceptibility and Age at Presentation with Prostate Cancer. *Lancet*, Vol.358, No.9282, (Aug 25), pp. 641-642, 0140-6736
- MacDonald, P.N., Baudino, T.A., Tokumaru, H., Dowd, D.R. & Zhang, C. (2001). Vitamin D Receptor and Nuclear Receptor Coactivators: Crucial Interactions in Vitamin D-Mediated Transcription. *Steroids*, Vol.66, No.3-5, (Mar-May), pp. 171-176, 0039-128X
- MacLaughlin, J. & Holick, M.F. (1985). Aging Decreases the Capacity of Human Skin to Produce Vitamin D3. *J Clin Invest*, Vol.76, No.4, (Oct), pp. 1536-1538, 0021-9738
- Majumder, P.K., Grisanzio, C., O'Connell, F., Barry, M., Brito, J.M., Xu, Q., Guney, I., Berger, R., Herman, P., Bikoff, R., Fedele, G., Baek, W.K., Wang, S., Ellwood-Yen, K., Wu, H., Sawyers, C.L., Signoretti, S., Hahn, W.C., Loda, M. & Sellers, W.R. (2008). A Prostatic Intraepithelial Neoplasia-Dependent P27 Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. *Cancer Cell*, Vol.14, No.2, (Aug 12), pp. 146-155, 1878-3686


- Matsuoka, L.Y., Wortsman, J., Haddad, J.G., Kolm, P. & Hollis, B.W. (1991). Racial Pigmentation and the Cutaneous Synthesis of Vitamin D. *Arch Dermatol*, Vol.127, No.4, (Apr), pp. 536-538, 0003-987X
- Maund, S.L., Barclay, W.W., Hover, L.D., Axanova, L.S., Sui, G., Hipp, J.D., Fleet, J.C., Thorburn, A. & Cramer, S.D. (2011). Interleukin-1 Alpha Mediates the Anti-Proliferative Effects of 1,25 Dihydroxyvitamin D3 in Prostate Progenitor/Stem Cells. *Cancer Res* Vol. 71, No. 15 (Aug 1):pp. 5276-5286
- Maund, S.L. & Cramer, S.D. (2009). Translational Implications of Stromal-Epithelial Interactions in Prostate Cancer and the Potential Role of Prostate Cancer Stem/Progenitor Cells. *The Handbook of Cell Signaling*, Vol. 3, No., pp. 2773-2782 978-0-12-374145-5
- Maund, S.L. & Cramer, S.D. (2010). The Tissue-Specific Stem Cell as a Target for Chemoprevention. *Stem Cell Rev*, Vol., No., (Nov 18), 1558-6804
- Mellanby, E. (1921). Experimental Rickets. *Spec Rep Ser Med Res Council (GB)*, Vol.SRS61, No.4,
- Miller, G.J., Stapleton, G.E., Ferrara, J.A., Lucia, M.S., Pfister, S., Hedlund, T.E. & Upadhyay, P. (1992). The Human Prostatic Carcinoma Cell Line Lncap Expresses Biologically Active, Specific Receptors for 1 Alpha,25-Dihydroxyvitamin D3. *Cancer Res*, Vol.52, No.3, (Feb 1), pp. 515-520, 0008-5472
- Miller, G.J., Stapleton, G.E., Hedlund, T.E. & Moffat, K.A. (1995). Vitamin D Receptor Expression, 24-Hydroxylase Activity, and Inhibition of Growth by 1alpha,25-Dihydroxyvitamin D3 in Seven Human Prostatic Carcinoma Cell Lines. *Clin Cancer Res*, Vol.1, No.9, (Sep), pp. 997-1003, 1078-0432
- Mimeault, M. & Batra, S.K. (2010). New Advances on Critical Implications of Tumor- and Metastasis-Initiating Cells in Cancer Progression, Treatment Resistance and Disease Recurrence. *Histol Histopathol*, Vol.25, No.8, (Aug), pp. 1057-1073, 1699-5848
- Muller, M. (2009). Cellular Senescence: Molecular Mechanisms, in Vivo Significance, and Redox Considerations. *Antioxid Redox Signal*, Vol.11, No.1, (Jan), pp. 59-98, 1557-7716
- Nakamura, K., Nashimoto, M., Hori, Y. & Yamamoto, M. (2000). Serum 25-Hydroxyvitamin D Concentrations and Related Dietary Factors in Peri- and Postmenopausal Japanese Women. *Am J Clin Nutr*, Vol.71, No.5, (May), pp. 1161-1165, 0002-9165
- Nelson, W.G., De Marzo, A.M. & Isaacs, W.B. (2003). Prostate Cancer. *N Engl J Med*, Vol.349, No.4, (Jul 24), pp. 366-381, 1533-4406
- Nomura, A.M., Stemmermann, G.N., Lee, J., Kolonel, L.N., Chen, T.C., Turner, A. & Holick, M.F. (1998). Serum Vitamin D Metabolite Levels and the Subsequent Development of Prostate Cancer (Hawaii, United States). *Cancer Causes Control*, Vol.9, No.4, (Aug), pp. 425-432, 0957-5243
- Park, S.Y., Cooney, R.V., Wilkens, L.R., Murphy, S.P., Henderson, B.E. & Kolonel, L.N. (2010). Plasma 25-Hydroxyvitamin D and Prostate Cancer Risk: The Multiethnic Cohort. *Eur J Cancer*, Vol.46, No.5, (Mar), pp. 932-936, 1879-0852

- Peng, L., Malloy, P.J. & Feldman, D. (2004). Identification of a Functional Vitamin D Response Element in the Human Insulin-Like Growth Factor Binding Protein-3 Promoter. *Mol Endocrinol*, Vol.18, No.5, (May), pp. 1109-1119, 0888-8809
- Peng, L., Wang, J., Malloy, P.J. & Feldman, D. (2008). The Role of Insulin-Like Growth Factor Binding Protein-3 in the Growth Inhibitory Actions of Androgens in Lncap Human Prostate Cancer Cells. *Int J Cancer*, Vol.122, No.3, (Feb 1), pp. 558-566, 1097-0215
- Prosser, D.E. & Jones, G. (2004). Enzymes Involved in the Activation and Inactivation of Vitamin D. *Trends Biochem Sci*, Vol.29, No.12, (Dec), pp. 664-673, 0968-0004
- Rachez, C. & Freedman, L.P. (2000). Mechanisms of Gene Regulation by Vitamin D(3) Receptor: A Network of Coactivator Interactions. *Gene*, Vol.246, No.1-2, (Apr 4), pp. 9-21, 0378-1119
- Reya, T., Morrison, S.J., Clarke, M.F. & Weissman, I.L. (2001). Stem Cells, Cancer, and Cancer Stem Cells. *Nature*, Vol.414, No.6859, (Nov 1), pp. 105-111, 0028-0836
- Rosen, C.J. (2011). Clinical Practice. Vitamin D Insufficiency. *N Engl J Med*, Vol.364, No.3, (Jan 20), pp. 248-254, 1533-4406
- Sarkar, F.H., Li, Y., Wang, Z. & Kong, D. (2010). The Role of Nutraceuticals in the Regulation of Wnt and Hedgehog Signaling in Cancer. *Cancer Metastasis Rev*, Vol.29, No.3, (Sep), pp. 383-394, 1573-7233
- Schwartz, G.G., Hill, C.C., Oeler, T.A., Becich, M.J. & Bahnson, R.R. (1995). 1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D3 and Prostate Cancer Cell Proliferation in Vivo. *Urology*, Vol.46, No.3, (Sep), pp. 365-369, 0090-4295
- Schwartz, G.G., Whitlatch, L.W., Chen, T.C., Lokeshwar, B.L. & Holick, M.F. (1998). Human Prostate Cells Synthesize 1,25-Dihydroxyvitamin D3 from 25-Hydroxyvitamin D3. *Cancer Epidemiol Biomarkers Prev*, Vol.7, No.5, (May), pp. 391-395, 1055-9965
- Severson, R.K., Nomura, A.M., Grove, J.S. & Stemmermann, G.N. (1989). A Prospective Study of Demographics, Diet, and Prostate Cancer among Men of Japanese Ancestry in Hawaii. *Cancer Res*, Vol.49, No.7, (Apr 1), pp. 1857-1860, 0008-5472
- Shepard, R.M., Horst, R.L., Hamstra, A.J. & DeLuca, H.F. (1979). Determination of Vitamin D and Its Metabolites in Plasma from Normal and Anephric Man. *Biochem J*, Vol.182, No.1, (Jul 15), pp. 55-69, 0264-6021
- Steddon, S.J., Schroeder, N.J. & Cunningham, J. (2001). Vitamin D Analogues: How Do They Differ and What Is Their Clinical Role? *Nephrol Dial Transplant*, Vol.16, No.10, (Oct), pp. 1965-1967, 0931-0509
- Studzinski, G.P. & Harrison, L.E. (1999). Differentiation-Related Changes in the Cell Cycle Traverse. *Int Rev Cytol*, Vol.189, No., pp. 1-58, 0074-7696
- Sung, V. & Feldman, D. (2000). 1,25-Dihydroxyvitamin D3 Decreases Human Prostate Cancer Cell Adhesion and Migration. *Mol Cell Endocrinol*, Vol.164, No.1-2, (Jun), pp. 133-143, 0303-7207
- Tagami, T., Lutz, W.H., Kumar, R. & Jameson, J.L. (1998). The Interaction of the Vitamin D Receptor with Nuclear Receptor Corepressors and Coactivators. *Biochem Biophys Res Commun*, Vol.253, No.2, (Dec 18), pp. 358-363, 0006-291X
- Tang, J.Y., Xiao, T.Z., Oda, Y., Chang, K.S., Shpall, E., Wu, A., So, P.L., Hebert, J., Bikle, D. & Epstein, E.H., Jr. (2011). Vitamin D3 Inhibits Hedgehog Signaling and Proliferation

- in Murine Basal Cell Carcinomas. *Cancer Prev Res (Phila)*, Vol.4, No.5, (May), pp. 744-751, 1940-6215
- Thompson, I.M., Tangen, C.M., Klein, E.A. & Lippman, S.M. (2005). Phase Iii Prostate Cancer Prevention Trials: Are the Costs Justified? *J Clin Oncol*, Vol.23, No.32, (Nov 10), pp. 8161-8164, 0732-183X
- Tokar, E.J. & Webber, M.M. (2005). Chemoprevention of Prostate Cancer by Cholecalciferol (Vitamin D3): 25-Hydroxylase (Cyp27a1) in Human Prostate Epithelial Cells. *Clin Exp Metastasis*, Vol.22, No.3, pp. 265-273, 0262-0898
- Tretli, S., Hernes, E., Berg, J.P., Hestvik, U.E. & Røbsahm, T.E. (2009). Association between Serum 25(OH)D and Death from Prostate Cancer. *Br J Cancer*, Vol.100, No.3, (Feb 10), pp. 450-454, 1532-1827
- Trottier, G., Bostrom, P.J., Lawrentschuk, N. & Fleshner, N.E. (2010). Nutraceuticals and Prostate Cancer Prevention: A Current Review. *Nat Rev Urol*, Vol.7, No.1, (Jan), pp. 21-30, 1759-4820
- Trump, D.L., Deeb, K.K. & Johnson, C.S. (2010). Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and Therapy. *Cancer J*, Vol.16, No.1, (Jan-Feb), pp. 1-9, 1540-336X
- Trump, D.L., Muindi, J., Fakih, M., Yu, W.D. & Johnson, C.S. (2006). Vitamin D Compounds: Clinical Development as Cancer Therapy and Prevention Agents. *Anticancer Res*, Vol.26, No.4A, (Jul-Aug), pp. 2551-2556, 0250-7005
- Vashi, P.G., Trukova, K., Lammersfeld, C.A., Braun, D.P. & Gupta, D. (2010). Impact of Oral Vitamin D Supplementation on Serum 25-Hydroxyvitamin D Levels in Oncology. *Nutr J*, Vol.9, No., pp. 60, 1475-2891
- Washington, M.N., Kim, J.S. & Weigel, N.L. (2011). 1alpha,25-Dihydroxyvitamin D3 Inhibits C4-2 Prostate Cancer Cell Growth Via a Retinoblastoma Protein (Rb)-Independent G1 Arrest. *Prostate*, Vol.71, No.1, (Jan 1), pp. 98-110, 1097-0045
- Whitlatch, L.W., Young, M.V., Schwartz, G.G., Flanagan, J.N., Burnstein, K.L., Lokeshwar, B.L., Rich, E.S., Holick, M.F. & Chen, T.C. (2002). 25-Hydroxyvitamin D-1alpha-Hydroxylase Activity Is Diminished in Human Prostate Cancer Cells and Is Enhanced by Gene Transfer. *J Steroid Biochem Mol Biol*, Vol.81, No.2, (Jun), pp. 135-140, 0960-0760
- Yang, E.S. & Burnstein, K.L. (2003). Vitamin D Inhibits G1 to S Progression in Lncap Prostate Cancer Cells through P27kip1 Stabilization and Cdk2 Mislocalization to the Cytoplasm. *J Biol Chem*, Vol.278, No.47, (Nov 21), pp. 46862-46868, 0021-9258
- Yasmin, R., Williams, R.M., Xu, M. & Noy, N. (2005). Nuclear Import of the Retinoid X Receptor, the Vitamin D Receptor, and Their Mutual Heterodimer. *J Biol Chem*, Vol.280, No.48, (Dec 2), pp. 40152-40160, 0021-9258
- Zehnder, D., Bland, R., Williams, M.C., McNinch, R.W., Howie, A.J., Stewart, P.M. & Hewison, M. (2001). Extrarenal Expression of 25-Hydroxyvitamin D(3)-1 Alpha-Hydroxylase. *J Clin Endocrinol Metab*, Vol.86, No.2, (Feb), pp. 888-894, 0021-972X
- Zhao, X.Y., Ly, L.H., Peehl, D.M. & Feldman, D. (1997). 1alpha,25-Dihydroxyvitamin D3 Actions in Lncap Human Prostate Cancer Cells Are Androgen-Dependent. *Endocrinology*, Vol.138, No.8, (Aug), pp. 3290-3298, 0013-7227

- Zhao, X.Y., Ly, L.H., Peehl, D.M. & Feldman, D. (1999). Induction of Androgen Receptor by 1alpha,25-Dihydroxyvitamin D3 and 9-Cis Retinoic Acid in Lncap Human Prostate Cancer Cells. *Endocrinology*, Vol.140, No.3, (Mar), pp. 1205-1212, 0013-7227
- Zhao, X.Y., Peehl, D.M., Navone, N.M. & Feldman, D. (2000). 1alpha,25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent Mechanisms. *Endocrinology*, Vol.141, No.7, (Jul), pp. 2548-2556, 0013-7227
- Zhuang, S.H. & Burnstein, K.L. (1998). Antiproliferative Effect of 1alpha,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line Lncap Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation. *Endocrinology*, Vol.139, No.3, (Mar), pp. 1197-1207, 0013-7227

IntechOpen



Prostate Cancer - From Bench to Bedside

Edited by Dr. Philippe E. Spiess

ISBN 978-953-307-331-6

Hard cover, 528 pages

Publisher InTech

Published online 25, November, 2011

Published in print edition November, 2011

The present textbook highlights many of the exciting discoveries made in the diagnosis and treatment of prostate cancer over the past decade. International thought leaders have contributed to this effort providing a comprehensive and state-of-the art review of the signaling pathways and genetic alterations essential in prostate cancer. This work provides an essential resource for healthcare professionals and scientists dedicated to this field. This textbook is dedicated to the efforts and advances made by our scientific community, realizing we have much to learn in striving to some day in the not too distant future cure this disease particularly among those with an aggressive tumor biology.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Sophia L. Maund and Scott D. Cramer (2011). The Role of Vitamin D in the Prevention and Treatment of Prostate Cancer, Prostate Cancer - From Bench to Bedside, Dr. Philippe E. Spiess (Ed.), ISBN: 978-953-307-331-6, InTech, Available from: <http://www.intechopen.com/books/prostate-cancer-from-bench-to-bedside/the-role-of-vitamin-d-in-the-prevention-and-treatment-of-prostate-cancer>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen